KeyBanc analyst Brett Fishbin reiterated an Overweight rating and $274.00 price target on ResMed (NYSE: RMD).The analyst commented: "For RMD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE